ARCHIVEDepend Sends a Fictional CEO to the Bathroom All Day
How Depend Used CEO Benjamin Dover to Reframe Incontinence Humour in 2017 Depend's 2017 United...
How Area 23 Turned Shingles Prevention Into Cinematic Storytelling
Shingles Stand In is a 2024 healthcare film campaign created by Area 23 for GSK's Shingrix shingles vaccine, published in the United States in January 2024, using cinematic narrative storytelling to reframe shingles prevention as a personal and emotionally resonant health decision for adults most at risk.
The campaign centres on a single narrative-driven film asset, catalogued under the internal identifier GXSJ0182000H Baby GSK Shingrix 12 14 22 AGENCY H264 2, with a video upload date of August 22, 2023. Area 23, an FCB Health network agency operating under WPP's broader healthcare communications umbrella, developed the work to address one of the most persistently underestimated adult vaccine categories in the United States. Shingles affects roughly one in three Americans over a lifetime, according to the US Centers for Disease Control and Prevention, making prevention messaging a genuine public health priority. The campaign's classification as unbranded — later confirmed by its London International Awards entries — positions it within a sophisticated creative tradition that builds category awareness and emotional permission before surfacing the product name directly.
The campaign's geographic market is the United States, and its Health industry classification reflects the tightly regulated nature of pharmaceutical advertising in that market. Shingles Stand In operates within what Clapboard identifies as the Narrative format, a designation that signals a story-first structure rather than a product-feature-led message. The Clapboard Score for this campaign is 63 out of 100, reflecting competent creative execution with room for broader cultural resonance and measurable audience engagement. The campaign's film medium situates it in a premium production context, signalling that GSK and Area 23 intended the work to carry credibility and emotional weight commensurate with a category leader defending a dominant market position.
Shingrix holds approximately 94 to 95 percent of shingles vaccine category revenue globally, according to Grand View Research, making it the dominant commercial force in a market estimated at between 4.8 and 4.9 billion dollars in 2024 by the same source. In the United States, where adult vaccination rates remain a persistent challenge, the strategic imperative for GSK is not simply to sell a product but to shift behavioural intent among adults who have not yet acted on a known health risk. Area 23's choice of an unbranded narrative format responds directly to that challenge.
Unbranded pharmaceutical advertising has a documented history of expanding category awareness before product-level messaging closes the sale. The approach is particularly effective in shingles vaccination, where the barrier is often emotional — adults underestimate personal risk or defer action — rather than informational. By leading with a human story rather than a clinical claim, Shingles Stand In creates the emotional permission structure that product advertising then leverages. This strategy mirrors a 2021 Area 23 Shingrix campaign for pharmacists, reported by MediaPost, which used satire and a mock behind-the-scenes film-production format to engage healthcare professionals rather than patients directly, demonstrating the agency's sustained commitment to unconventional formats for this brand.
In the United States, competing shingles vaccine options are limited; Zostavax, once Merck's primary entry, was withdrawn from the US market in 2020, according to the US Food and Drug Administration, leaving Shingrix with near-total category ownership. That absence of a direct branded competitor makes category-level storytelling a logical investment: growing total vaccine uptake benefits Shingrix almost exclusively. The US shingles vaccine market's projected compound annual growth rate of between 10.1 and 15.7 percent through 2030, according to Grand View Research, reinforces the commercial logic of sustained creative investment in narrative-driven awareness work.
Shingles Stand In deploys the film medium as its sole creative channel, a deliberate choice that privileges emotional depth over media reach. The campaign's single media asset, produced in an H264 video format consistent with broadcast and digital streaming delivery, reflects a production approach oriented toward quality of encounter rather than quantity of impressions. The unbranded execution places narrative construction at the centre of the creative challenge: without a brand name to anchor audience recognition, the film must earn and sustain attention through character, situation, and emotional truth alone.
Production credits for Shingles Stand In are not publicly documented in available trade sources. What the archive record does establish is that Area 23, a New York-based agency with a specialist healthcare advertising practice, led creative development. The agency has demonstrated a consistent craft sensibility across its Shingrix work: its 2021 pharmacist-targeted campaign, noted by MediaPost, used a high-production mock documentary format to blend comedy and information, suggesting a house style that trusts cinematic form to carry complex health messaging. The Shingles Stand In film extends that tradition into the patient-facing space, using the Narrative format to construct a scenario — implied by the campaign title — in which a shingles-related situation plays out through character experience rather than voiceover instruction.
The London International Awards recognised two executions within the broader Shingles Stand In campaign in 2025: Surprise Party, which received a Silver award in the Unbranded Pharmaceuticals and Vaccines category, and New Baby, which received a Bronze in the same category, as confirmed by the London International Awards. Both titles suggest domestic, life-milestone scenarios chosen to make shingles risk personally vivid for adults at the age of highest vulnerability. The creative strategy of embedding vaccine messaging inside emotionally familiar life events is a craft decision as much as a strategic one, requiring writers and directors to subordinate product logic to human truth.
No verified independent performance data for the Shingles Stand In campaign — such as reach figures, vaccination intent lift, or media spend — is publicly available from GSK, Area 23, or third-party measurement sources. What the public record does confirm is that the campaign earned formal industry recognition at a significant level. Area 23 received a Silver award at the London International Awards in 2025 for the Surprise Party execution and a Bronze for the New Baby execution, both entered in the Unbranded Pharmaceuticals and Vaccines category, as confirmed by the London International Awards.
The campaign's archived video asset recorded 436 views at the time of cataloguing, with no documented likes or comments, according to Clapboard's archive data. These figures are consistent with an unbranded healthcare film that circulates primarily through professional and clinical channels rather than consumer-facing social platforms — a distribution pattern that limits public engagement metrics without diminishing campaign effectiveness in its intended context. The structural effectiveness of the campaign rests on two observable strengths: the emotional specificity of its life-milestone scenarios, which are designed to convert passive awareness into active health intent, and the agency's demonstrated ability to earn award recognition in a category where creative ambition is frequently constrained by regulatory requirements.
The Clapboard Score for Shingles Stand In is 63 out of 100. This score reflects a campaign that executes its narrative brief with professional competence and earns industry validation, while its limited documented reach and engagement ceiling in the public domain prevent a higher rating. For a market in which Shingrix generated approximately 4.2 billion dollars in estimated 2024 revenue, according to Grand View Research, sustained creative investment in narrative-driven prevention messaging represents a proportionate and strategically sound commitment.
Shingles Stand In is a 2024 unbranded healthcare film campaign created by Area 23 for GSK's Shingrix shingles vaccine in the United States. It uses narrative storytelling set in relatable life-milestone scenarios to make shingles prevention personally relevant to adults most at risk, and later earned recognition at the London International Awards in 2025.
Area 23, a specialist healthcare advertising agency, created Shingles Stand In for GSK and its Shingrix shingles vaccine. The campaign was published in the United States in January 2024 and classified as unbranded, meaning it builds category awareness without leading with the Shingrix product name in the film itself.
The London International Awards recognised two Shingles Stand In executions in 2025. Surprise Party received Silver and New Baby received Bronze, both in the Unbranded Pharmaceuticals and Vaccines category. These awards confirm the campaign's standing as a creatively distinguished piece of healthcare communications within a tightly regulated advertising environment.
Unbranded advertising builds emotional permission before product messaging intervenes, a strategy particularly effective when the audience underestimates personal risk. For Shingrix, which holds approximately 94 to 95 percent of shingles vaccine category revenue according to Grand View Research, expanding total vaccination intent in the United States benefits the brand almost exclusively given limited direct competition.
Shingles Stand In holds a Clapboard Score of 63 out of 100. The score reflects competent narrative execution and confirmed industry award recognition at the London International Awards, balanced against limited documented public reach and engagement. It positions the campaign as professionally strong within healthcare advertising while noting headroom for broader cultural impact.
.webp)
Creative Collaboration Platform: The Backbone of Modern Creative WorkWhat is a creative collaboration platform?Clapboard defines a creative collaboration platform as the operational core for today’s distributed creative teams. This is not a collection of digital collaboration tools stitched together; Clapboard’s system
Understanding the Creative Production MarketplaceWhat is a Creative Production Marketplace?Clapboard defines a creative production marketplace as a structured ecosystem where brands, agencies, and production talent converge to execute video, advertising, and branded content at scale. Unlike the legacy agency or freelanREAD FULL ARTICLE
The Urgent Need for a Creative Production Operating SystemWhy Traditional Creative Production Models Break DownClapboard sees the creative production landscape shifting under pressure. Content velocity is no longer a buzzword—it’s a mandate. Modern advertising demands relentless output across dozens of channels, each wREAD FULL ARTICLE
.jpg&w=256&q=75)
